Tamoxifen
is an SERM, also known as a selective estrogen receptor modulator which affects
estrogen levels in gynecomastia with the antagonistic actions on estrogen
receptors. Gynecomastia is a benign enlargement of breast tissue; it mostly
occurs due to an imbalance between estrogen and testosterone levels, which
leads to increased estrogen activity relative to androgens, the male puberty
hormone.
Tamoxifen,
similar to enzyme inhibitors, binds to estrogen receptors, specifically alpha
and beta estrogen receptors in breast tissue. By occupying the receptors,
tamoxifen blocks estrogen from binding to the receptors, thus inhibiting ESPs
(estrogen signaling pathways). By doing this, the antagonistic action, it
reduces the effect of estrogen on breast tissue growth or size.
The
medicine also may induce cell apoptosis in breast tissue, killing off the cells
that lead to the swollen look of the chest that most people with gynecomastia
have. Through this, it causes a regression in the volume of the chest and makes
it appear smaller by getting rid of the unnecessary bulk.
This is
also supported by clinical trial analyses. For example, when a group of ten
people were subjected to placebos of tamoxifen and the real tamoxifen, 7 out of
10 people responded to the tamoxifen with a decrease in chest size, while none
of the people responded to the placebo; thus, showing us the efficacy of tamoxifen
as a treatment for gynecomastia.
However,
since tamoxifen acts on hormones which are crucial to the body in right
amounts, consuming tamoxifen can have an adverse effect on the body unless
prescribed by a specialist after checking hormone levels with the appropriate
test.
Comments
Post a Comment
Please add your name when you comment down below!